Who makes Dasatinib 100 MG?

Dasatinib 100 MG is developed by Cedars-Sinai Medical Center.

What development phase is Dasatinib 100 MG in?

Dasatinib 100 MG is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Dasatinib 100 MG

Cedars-Sinai Medical Center · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Dasatinib 100 MG
Also known as	Sprycell, sprycel, Sprycel, BMS-354825
Sponsor	Cedars-Sinai Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Improving Physical Ability and Cellular Senescence Elimination in HIV (PHASE2)
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects (PHASE2, PHASE3)
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (PHASE3)
Dasatinib for HIV-1 Reservoir Reduction (PHASE1)
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease (PHASE1, PHASE2)
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (PHASE2)
Senolytics to Improve Osteoporosis Therapy (PHASE2)
ALSENLITE: Senolytics for Alzheimer's Disease (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dasatinib 100 MG CI brief — competitive landscape report
Dasatinib 100 MG updates RSS · CI watch RSS
Cedars-Sinai Medical Center portfolio CI